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Abstract
The c-Jun N-terminal kinase (JNK) - 1 pathway has been implicated in the cellular response to stress in many tissues and
models. JNK1 is known to play a role in a variety of signaling cascades, including those involved in lung disease
pathogenesis. Recently, a role for JNK1 signaling in immune cell function has emerged. The goal of the present study was to
determine the role of JNK1 in host defense against both bacterial and viral pneumonia, as well as the impact of JNK1
signaling on IL-17 mediated immunity. Wild type (WT) and JNK1 2/2 mice were challenged with Escherichia coli,
Staphylococcus aureus, or Influenza A. In addition, WT and JNK1 2/2 mice and epithelial cells were stimulated with IL-17A.
The impact of JNK1 deletion on pathogen clearance, inflammation, and histopathology was assessed. JNK1 was required for
clearance of E. coli, inflammatory cell recruitment, and cytokine production. Interestingly, JNK1 deletion had only a small
impact on the host response to S. aureus. JNK1 2/2 mice had decreased Influenza A burden in viral pneumonia, yet
displayed worsened morbidity. Finally, JNK1 was required for IL-17A mediated induction of inflammatory cytokines and
antimicrobial peptides both in epithelial cells and the lung. These data identify JNK1 as an important signaling molecule in
host defense and demonstrate a pathogen specific role in disease. Manipulation of the JNK1 pathway may represent a novel
therapeutic target in pneumonia.
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Introduction
Bacterial and viral pneumonia represents a significant cause of
morbidity and mortality worldwide. Bacterial pneumonia is a
commonly encountered lung infection in both hospital acquired
and community acquired settings. Infection with either gram
negative or gram positive bacteria results in lung inflammation,
tissue damage, and in some cases life-threatening sepsis. Despite
numerous antibiotic therapies, these infections often result in poor
patient outcomes. Influenza A infection by either seasonal or
pandemic virus is of increasing epidemiologic importance in recent
years. Influenza A infection results in lung cell apoptosis, injury,
and remodeling. In worst cases, severe inflammation and co-
infection may lead to mortality. Anti-viral therapies are effective at
reducing viral burden; however, lung injury often persists. The
need for identification of novel pathways in pneumonia patho-
genesis is great in order to design new therapeutic approaches.
Many cellular signaling pathways have been investigated for their
role in these processes.
The MAPK family member c-Jun N-terminal kinase (JNK)
comprises three members, JNK1–3, with numerous alternate
splicoforms [1]. JNK1 and JNK2 are ubiquitously expressed, while
JNK3 is restricted to the brain, testes, and heart. JNK1 is known to
play a role in cellular stress responses, apoptosis [2], and was
recently shown to modulate lung remodeling following injury [3–
5]. The JNK1 signaling pathway is complex and its roles in both
innate and adaptive immune responses have been recently
reviewed [1–2,6–7]. A primary consequence of JNK1 activation,
via phosphorylation by upstream kinases, is phosphorylation of
AP-1 transcription factors, including c-Jun. In this manner JNK1
plays an important role in transcriptional regulation in response to
a number of stimuli. JNK1 is activated by the gram-negative
bacterial component lipopolysaccharide (LPS) via TLR4 [8–9]
and JNK1 is required for chemokine production by macrophages
[10–11]. These data suggest an important role for JNK1 in innate
immune responses. JNK1 has also been shown to play a role in
regulating helper T cell function. Naı ¨ve CD4
+ T cells express low
levels of JNK1 and JNK2, however upon activation, these proteins
are highly upregulated and display increased activity [1]#. These
data define an emerging role for JNK in both innate and adaptive
immunity.
The goal of this study was to investigate the role of JNK1 in host
defense against bacterial and viral pneumonia. In addition, the
potential immunologic mechanism by which JNK1 interacts was
examined. IL-17A has been implicated in host defense against
many pathogens, both intra- and extra-cellular in nature. The
impact of JNK1 on IL-17A signaling was also addressed. Since
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34638many prior studies evaluating the role of JNK1 in inflammation
have utilized non-specific pharmacologic inhibitors in cell lines,
these studies were conducted utilizing JNK1 2/2 mice and
primary epithelial cells from mice lacking JNK1.
Results
JNK1 regulates lung inflammation in bacterial
pneumonia
JNK1 is known to modulate numerous responses to cellular
stress including inflammatory stimuli. The majority of studies
addressing the role of JNK1 in host defense have utilized non-
specific inhibitor approaches, often employing in vitro approaches.
To examine whether JNK1 is required for bacterial host defense in
vivo, we challenged WT and JNK1 2/2 mice with the gram-
negative bacterium E. coli. JNK1 2/2 mice displayed a nearly
four-fold increase in bacterial burden in the lung one day after
challenge (Figure 1A, B). While total inflammatory cell recruit-
ment in BAL was not different, the profile of cells in JNK1 2/2
mice was characterized by significantly less macrophages than WT
mice. To further examine the impact of JNK1 deletion on
inflammation, we examined lung histopathology. JNK1 2/2
mice had significantly decreased peribronchial inflammation
compared to WT mice (Figure 2). JNK1 2/2 mice trended
towards having reduced overall lung parenchymal inflammatory
cellular infiltrates. Next, the effect of JNK1 depletion on cytokine
induction was examined by cytokine multiplex assay. JNK1 2/2
mice produced significantly less MCP-1, IFNc, IP-10, and IL-1a
versus WT mice (Figure 1C, D). In addition, JNK1 2/2 mice had
a trend towards decreased IL-6, TNFa, and IL-17A production.
Since IL-23 is required for IL-17A production, we measured IL-
23p19 in the lung homogenate. WT and JNK1 2/2 mice
Figure 1. JNK1 is required for host defense against gram-negative bacterial pneumonia. WT and JNK1 2/2 mice were challenged with
10
7 cfu of E. coli for 24 hours (N=8, 10). A – bacterial colony counts in lung homogenate. B – inflammatory cells in BAL fluid. C, D – inflammatory
cytokines in lung homogenate. E – antimicrobial peptide expression in lung tissue. F – inflammatory cells in BAL fluid from mice challenged with PBS
for 24 hours (N=6, 6). * p,0.05, # p,0.10.
doi:10.1371/journal.pone.0034638.g001
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250.5628.8 pg/ml, respectively) in response to E. coli challenge.
We then examined whether JNK1 was required for antimicrobial
peptide production in response to E. coli. JNK1 2/2 mice
produced significantly less Reg3b and a trend towards less Camp
compared to WT mice (Figure 1E). Finally, to confirm that the
difference in cellular inflammation between WT and JNK1 2/2
mice was not due to baseline differences between the mice, WT
and JNK1 2/2 mice were challenged with PBS for 24 hours.
Differential BAL cell counts showed no changes in macrophage
numbers between the mouse strains (Figure 1F). These data
indicate that JNK1 is required for the normal immune response to
the gram-negative bacteria E. coli. Deletion of JNK1 resulted in
decreased lung inflammation and increased pathogen burden.
E. coli, and other gram-negative bacteria, drives inflammation
through interaction of LPS with the Tlr4 signaling cascade [12].
Gram-positive bacteria initiate inflammation largely through
interactions with Tlr2 and other pathways [13]. To test whether
JNK1 plays a role in host defense against gram-positive bacteria,
we challenged WT and JNK1 2/2 mice with S. aureus. JNK1 2/
2 mice did not have significantly elevated S. aureus burden one day
after challenge (Figure 3). Similar to the E. coli challenge model,
JNK1 2/2 and WT mice had similar BAL cell numbers, but
JNK1 2/2 mice recruited significantly less macrophages.
Deletion of JNK1 resulted in significantly less IL-1a production,
but did not impact other cytokines that were decreased in the
gram-negative model. These data suggest that JNK1 does not play
a large role in host defense or inflammation in response to the
gram positive bacterium S. aureus.
JNK1 modulates the pathophysiology of Influenza A
infection
Studies presented thus far addressed the role of JNK1 in host
defense against extracellular pathogens. Next, the role of JNK1 in
intracellular host defense was evaluated. WT and JNK1 2/2
mice were infected with Influenza A PR/8/34 H1N1 for seven
days. JNK1 2/2 mice displayed increased weight loss throughout
the infection time course compared to WT mice (Figure 4A).
Interestingly, despite having greater morbidity as measured by
weight loss, JNK1 2/2 mice had decreased viral burden
(measured by viral matrix protein expression) versus WT mice
on day seven (Figure 4B, C). The total number of BAL
inflammatory cells was unaltered in JNK1 2/2 mice, however,
these mice had significantly decreased macrophage recruitment
Figure 2. JNK1 is required for peribronchial inflammation during gram-negative bacterial pneumonia. WT and JNK1 2/2 mice were
challenged with 10
7 cfu of E. coli for 24 hours (N=8, 10). A – lung histology 1006(top panels), 2006(lower panels). B – lung histology scoring.
*p ,0.05.
doi:10.1371/journal.pone.0034638.g002
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(Figure 5A). One possible explanation for increased morbidity
would be an enhanced inflammatory profile or cytokine storm in
JNK1 2/2 mice. Analysis of tissue inflammation by histopathol-
ogy revealed no differences in parenchymal or peribronchial
inflammation (Figure 6A, B). Consistent with the small changes in
inflammation observed, JNK1 2/2 mice had significantly
reduced KC and IL-10 production, but many cytokines were
unaffected versus WT mice (Figure 5B–D). IL-23p19 production
trended towards decreased production in JNK1 2/2 compared
to WT mice (Figure 5E). Overall, these data show that JNK1 plays
a minor role in lung inflammation induced by Influenza A, but is
critical to determining morbidity and viral burden. One
potentially key difference observed in JNK1 2/2 mice by
histopathology was the presence of plugging of airways (Figure 6A).
This phenotype was not observed in any sections from WT mice.
To determine if the airway plugging was perhaps due to mucus
hyper-production, expression of Muc5ac, Muc5b, and Clca3 were
examined. JNK1 2/2 mice did not display different levels of
mucin gene expression versus WT mice (Figure 6C). In addition,
neither WT nor JNK1 2/2 mice stained positive for mucus
hyper-production by Periodic Acid Schiff staining (data not
shown). Finally, the mechanism by which JNK1 2/2 mice have
lower Influenza A burden was investigated. The type I interferon
response has been shown to be critical to improving viral host
defense and clearance. WT and JNK1 2/2 mice produced
similar levels of IFNb seven days after infection, suggesting no
defect or enhancement of this pathway (Figure 7A). Since JNK1
has been shown to play a role in T cell survival, the impact of
JNK1 deletion on T cell populations in the lung following viral
infection was assessed. JNK1 2/2 mice displayed similar ratios of
CD4
+, CD8
+, cdT, and NKT cells as WT mice (Figure 7B). These
data suggest that JNK1 2/2 mice have appropriate T cell
responses to Influenza A infection.
JNK1 is required for IL-17A signaling in vitro and in vivo
The IL-17 pathway has recently been implicated in host defense
against a number of both intra- and extra-cellular pathogens. IL-
17A is known to be required for host defense and inflammation in
response to gram-negative and gram-positive bacteria, as well as
Influenza A infection. In models of bacterial pneumonia IL-17R
signaling or IL-17A is required for pathogen clearance. In contrast
in Influenza A infection, IL-17R signaling is dispensable for viral
clearance, but is required for morbidity and lung injury [14–17].
Since JNK1 has a role in these infection paradigms and JNK1 2/
2 mice had a trend towards decreased IL-17A production, the
role of JNK1 in IL-17A signaling was investigated. First, to
confirm that IL-17A stimulates JNK1 activity, mouse tracheal
Figure 3. JNK1 is not required for host defense against gram-positive pneumonia. WT and JNK1 2/2 mice were challenged with 10
8 cfu
of S. aureus for 24 hours (N=5, 8). A – bacterial colony counts in lung homogenate. B – inflammatory cells in BAL fluid. C, D, E – inflammatory
cytokines in lung homogenate. * p,0.05.
doi:10.1371/journal.pone.0034638.g003
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phosphorylation of c-Jun was determined (Figure 8A). IL-17A
induced rapid activation of JNK1 as early as fifteen minutes after
stimulation. IL-17A is known to stimulate inflammatory cytokine
and antimicrobial peptide production by epithelial cells. WT and
JNK1 2/2 MTEC were stimulated with IL-17A for one day and
cytokines were measured by multiplex cytokine assay and RT-
PCR. IL-17A induced KC and MIP-2 protein and mRNA as well
as decreased IP-10 protein were significantly decreased in JNK1
2/2 MTEC compared to WT cells (Figure 8B–D). Surprisingly,
JNK1 2/2 MTEC had increased G-CSF mRNA, but no change
in protein compared to WT cells, upon stimulation with IL-17A
(Figure 8E). These data demonstrate that JNK1 is required for IL-
17A pro-inflammatory signaling in vitro. In addition, JNK1 2/2
MTEC expressed significantly decreased levels of the antimicro-
bial peptides S100a8 and Defb4 compared to IL-17A stimulated
WT MTEC (Figure 8F). Taken together, the data suggest that IL-
17A signals through JNK1 to induce inflammation and enhance
host defense.
Since JNK1 was shown to play a role in IL-17A signaling in
vitro in epithelial cells, the impact of JNK1 deletion on IL-17A
signaling in vivo was investigated. WT and JNK1 2/2 mice were
challenged with adenovirus expressing IL-17A for three days.
Adenoviral IL-17A induced similar levels of IL-17A protein in the
lung; 4088.161069.5 pg/ml in WT mice and 4009.46459.0 pg/
ml in JNK1 2/2 mice. The total numbers of inflammatory cells
in the BAL were similar in WT and JNK1 2/2 mice, however,
JNK1 2/2 mice had significantly increased macrophage and
decreased neutrophil recruitment (Figure 9A). In addition to
altered cellular infiltrate profiles, JNK1 2/2 mice produced
significantly decreased MCP-1 and IFNc compared to WT mice
(Figure 9B, C). The adenoviral expression approach utilized
introduces the potential caveat of a differential viral response in
the WT and JNK1 2/2 mice. To further examine IL-17A
signaling in vivo, WT and JNK1 2/2 mice were instilled with
recombinant mouse IL-17A for one day. IL-17A induced
significantly decreased MCP-1 and G-CSF production, as well
as a trend towards lower IP-10 and IFNc, in JNK1 2/2 mice
versus WT mice (Figure 9D, E). Furthermore, JNK1 2/2 mice
stimulated with IL-17A demonstrated a trend towards decreased
antimicrobial peptides S100a8 and S100a9 compared to WT mice
(Figure 9F). These data show that IL-17A requires JNK1 for
inflammatory signaling in vivo.
Discussion
The results of this study indicate that JNK1 plays a context
dependent role in host defense and inflammation. In general,
JNK1 was associated with macrophage recruitment in response to
each of the three pathogens tested. Furthermore, JNK1 was
necessary for induction of MCP-1 and IFNc, two important
factors for macrophage function. JNK1 was also implicated in the
production of antimicrobial peptides by epithelial cells and in the
lung. These data suggest two potential mechanisms by which
JNK1 may regulate host defense. In viral pneumonia, JNK1 had a
somewhat paradoxical role, as JNK1 2/2 mice had lower viral
burden but worsened morbidity and lung histopathology. The
mechanism for this did not appear to involve altered mucin gene
induction based on the lack of impact on Clca3 mRNA, T cell
recruitment, or type I interferon induction. Finally, JNK1
impacted IL-17A signaling in a similar manner to its effects on
gram-negative bacterial pneumonia; decreased chemokine and
antimicrobial peptide production. These data suggest that IL-17A
requires JNK1 signaling which would suggest that JNK1 is
required in a number of disease pathologies.
The impact of JNK1 in host defense against bacterial pathogens
is largely unclear. Little is known about the impact of JNK1
deletion or inhibition in vivo. Pseudomonas aeruginosa induces JNK1
dependent apoptosis of cells via its exotoxin S, E. coli mediated
induction of cytokines in HeLa cells was shown to be decreased by
Figure 4. JNK1 regulates host defense against Influenza A infection. WT and JNK1 2/2 mice were challenged with 150 pfu of Influenza A
PR/8/34 H1N1 for 7 days. A – weight loss during infection (N=9, 8). B – viral burden by plaque assay (N=4, 4). C – viral burden by RT-PCR for M
protein expression (N=9, 8). * p,0.05.
doi:10.1371/journal.pone.0034638.g004
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dependent [18–20]. These data support the findings that JNK1
may be important in host defense against gram-negative bacteria.
Our data indicate that JNK1 deletion has similar effects on E. coli
and IL-17A induced cytokine production. Specifically, IFNc and
MCP-1 levels were reduced in JNK1 2/2 mice challenged with
both stimuli. These data suggest that JNK1 may play a role in
macrophage function in host defense. E. coli has been previously
shown to activate JNK1 in macrophages [21]. Furthermore,
MCP-1 2/2 mice fail to recruit neutrophils during E. coli
pneumonia and have increase bacterial burden in the lung [22].
The link between IL-17A and E. coli pneumonia is supported by
the findings that LPS activates IL-17A production in the lung and
IL-17A 2/2 mice have increased E. coli burden in urinary tract
infection [23–24]. In addition, RIP2 2/2 mice have increased
bacterial burden and decreased IL-17A production in the lung
[25]. These data suggest that JNK1 may act downstream of IL-
17A during E. coli pneumonia. The lack of an impact of JNK1 on
host defense against gram-positive bacteria has not been previously
reported. Peptidoglycan from S. aureus was shown to require JNK1
to drive IL-8 production in lung type II cells, suggesting a role for
JNK1 [26]. Our data show a defect in macrophage recruitment
but little impact on cytokine production.
Recent studies concerning JNK1 and Influenza A infection have
focused on the ability of virus to inhibit JNK1 and thus alter host
cell apoptosis [27–28]. JNK1 was shown to be inhibited via viral
NS1 protein or host PI3K/AKT activity thus blocking apoptosis of
infected cells. These data would suggest that in the absence of
JNK1, viral burden may be increased due to a lack of apoptosis,
however we observed decreased viral burden in JNK1 2/2 mice.
MLK3 2/2 mice, a kinase upstream of JNK1, display increased
Influenza A burden due to increased epithelial cell survival and
viral replication [29]. The reason for the discrepancy with these
data and our findings is unclear. Several studies have reported
JNK1 activation following Influenza A infection [30–32]. In these
studies Influenza A drove activation of JNK1, downstream AP-1
transcriptional activity, and cytokine production. Our data show
that JNK1 deletion results in an altered inflammatory cellular
phenotype in the lung and suppression of KC and IL-10
production. A recent microarray study with a JNK1 inhibitor
showed decreased Influenza A induced IL-6 production, although
in JNK1 2/2 mice we did not observe this [33]#. Our data show
Figure 5. JNK1 modulates Influenza A induced inflammation. WT and JNK1 2/2 mice were challenged with 150 pfu of Influenza A PR/8/34
H1N1 for 7 days. A – inflammatory cells in BAL fluid. B, C, D, E – inflammatory cytokines in lung homogenate. * p,0.05, # p,0.10.
doi:10.1371/journal.pone.0034638.g005
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the BAL, but no change in the relative proportion of T cells versus
WT mice. JNK1 has been shown to be required for CD8
+ T cell
proliferative responses to IL-2, via regulation of IL-2 receptor,
CD25 [34]. A separate study showed that CD8
+ T cell apoptosis
requires JNK1 [35]#. These findings suggest opposing mecha-
nisms by which JNK1 deletion would be expected to either
increase or decrease CD8
+ T cells in response to Influenza A. Our
findings indicate a minimal effect on CD8
+ T cell populations in
the lung. At this time it remains to be determined why JNK1 2/2
mice have lower viral burden, but worsened morbidity during
Influenza A infection.
Figure 6. JNK1 alters lung histopathology during Influenza A infection. WT and JNK1 2/2 mice were challenged with 150 pfu of Influenza
A PR/8/34 H1N1 for 7 days. A – lung histology 2006(N=9, 8). B – lung histology scoring (N=9, 8). C – mucin gene expression by RT-PCR (N=9, 8).
doi:10.1371/journal.pone.0034638.g006
Figure 7. JNK1 is not required for antiviral interferon or T cell recruitment in response to Influenza A. WT and JNK1 2/2 mice were
challenged with 150 pfu of Influenza A PR/8/34 H1N1 for 7 days. A – type I interferon expression by RT-PCR (N=9, 8). B – T cell profile in lung
homogenate by flow cytometry (N=7, 9).
doi:10.1371/journal.pone.0034638.g007
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have been recently described. In a number of diverse cell types,
including airway smooth muscle cells and fibroblasts, IL-17A was
shown to stimulate phosphorylation of JNK1 and promote
cytokine production [36–44]. In these studies, pharmacologic
inhibition showed that JNK1 is required for the IL-17A induced
production of inflammatory mediators such as, IL-6, IL-8, eotaxin-
1, and b-defensin 2. These data suggest that JNK1 is an important
downstream signaling kinase in IL-17A induced inflammatory
responses. Conversely, a few studies have failed to find a role for
JNK1 downstream of IL-17A in epithelial cells [45–46]. A
limitation of these studies is the use of pharmacological inhibitors
which are somewhat non-specific and inhibit both JNK1 and
JNK2. JNK1 likely impacts IL-17A signaling at the transcriptional
level. AP-1 DNA-binding elements have been identified in the
promoter regions of IL-17A-induced genes, including IL-6, KC,
G-CSF, and MCP-1, indicating a potential target for JNK1
regulation [47]. The role of JNK1 within T cells is an active area
of investigation. JNK1 has previously been shown to play a role in
TH1/TH2 polarization and cytokine production [48], although its
role in differentiation of TH17 cells is unknown. The impact of
JNK1 deficiency with regards to IL-17A and airway epithelial cells
was previously unclear. Our data show that JNK1 is required for
induction of IFNc, MCP-1, G-CSF and antimicrobial peptides.
These data define a clear role for an IL-17A/JNK1 signaling axis
in lung primary epithelial cells relevant to lung infection and in
whole lung tissue.
The findings presented in this study indicate a diverse role for
JNK1 in host defense in the lung. The potential role for JNK1 in
regulation of macrophage responses in vivo is intriguing and
Figure 8. JNK1 is required for the epithelial cell response to IL-17A. MTEC from WT and JNK1 2/2 mice were treated with IL-17A (10 ng/ml)
for 24 hours. A – JNK1 activation by in vitro kinase assay. B, C – inflammatory cytokines produced (N=6). D, E – inflammatory cytokine gene
expression by RT-PCR (N=3). F – antimicrobial peptide expression by RT-PCR (N=3). * p,0.05.
doi:10.1371/journal.pone.0034638.g008
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regulating antimicrobial peptide production may have broad
consequences in immunity against numerous extracellular patho-
gens. Finally, the impact of JNK1 on viral clearance and
pathogenesis is intriguing and remains to be elucidated. Since
JNK1 modulates some of the functional effects of IL-17A, it is
likely that JNK1 is required for host defense in a number of TH17
mediated diseases. These data identify the JNK1 pathway as an
important target in understanding lung immunity. Targeting
JNK1 may provide a novel therapeutic approach for treating
pneumonia.
Materials and Methods
Animals
Heterozygous JNK1 +/2 mice on a N5 generation C57BL/6
background were purchased from Jackson Laboratories and were
maintained as a breeding colony under pathogen free conditions.
All experiments were conducted with age and sex matched JNK1
2/2 and wild-type (WT) littermate controls. All animal studies
were approved by the University of Pittsburgh Institutional
Animal Care and Use Committee, protocol #0903113.
Figure 9. JNK1 modulates the inflammatory response to IL-17A in vivo. WT and JNK1 2/2 mice were challenged with 5610
8 pfu of
adenovirus expressing IL-17A for 3 days (A–C) (N=8, 7) or 1 mg of recombinant IL-17A for 24 hours (D–F)(N=6, 7). A – inflammatory cells in BAL fluid.
B, C, D, E – inflammatory cytokines in lung homogenate. F – antimicrobial peptide expression in lung tissue. * p,0.05, # p,0.10, nd – not detected.
doi:10.1371/journal.pone.0034638.g009
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JNK1 2/2 and WT mice were inoculated with Escherichia coli
(DH5a,1 0
7 cfu) or Staphylococcus aureus (ATCC 49775, 10
8 cfu) by
oropharyngeal aspiration in 50 ml of sterile PBS. Bacteria were
grown for 18 hours to stationary phase prior to inoculation.
Twenty-four hours following infection, mice were lavaged with
1 ml sterile PBS for differential cell counts by cytospin. The right
lung was then homogenized in 1 ml sterile PBS for bacterial
colony counting, cytokine analysis by multiplex assay or by ELISA
for IL-23p19, and real-time PCR for gene expression. The left
lung was fixed in 10% neutral buffered formalin for histologic
processing and H&E staining. Lung parenchymal and peribron-
chial inflammation were scored on double-blinded sections using a
0, least inflamed to 3, most inflamed. Each slide was scored twice
and data reflect the cumulative inflammation score.
Influenza A Infection Model
JNK1 2/2 and WT mice were inoculated with Influenza A
PR/8/34 H1N1 virus (150 pfu). Infected mice were then
maintained for 7 days prior to harvest. Mouse lungs were lavaged
and processed as detailed above. Viral burden was determined by
viral plaque assay as previously described or by RT-PCR for viral
matrix (M) protein expression [14]. T cell recruitment to the lung
following Influenza A infection was determined by flow cytometry.
Briefly, whole mouse lungs were digested with collagenase
followed by mechanical separation. Lung cells were then stained
with fluorescent conjugated antibodies to the surface markers
CD4, CD8, cdTCR, and CD49b (DX5).
Mouse Tracheal Epithelial Cell (MTEC) Culture
MTEC were prepared and propagated as previously described
[3]. Cells were isolated from WT and JNK1 2/2 mice and were
maintained in submerged culture for studies with IL-17A. IL-17A
was added to MTEC cultures at a concentration of 10 ng/ml for
24 hours or as indicated.
JNK1 Kinase Assay
JNK1 activity in protein homogenates from MTEC was
determined as previously described [4]. Briefly, JNK1 was
immunoprecipitated from homogenates using anti-JNK1 antibody
(Santa Cruz Biotechnology). JNK1 was then incubated with P32-
ATP and a GST-c-Jun substrate for 30 minutes at 30uC.
Phosphorylation of GST-c-Jun was then visualized by SDS-PAGE
and autoradiography imaging.
Exogenous IL-17A Models
Adenovirus expressing IL-17A was generated as previously
described [16]#. WT and JNK1 2/2 mice were instilled with
5610
8 pfu of adenovirus expressing IL-17A by oropharyngeal
aspiration. Mice were then incubated for 3 days prior to harvest.
Mouse lungs were lavaged and processed as described above.
Additionally, WT and JNK1 2/2 mice were instilled with 1 mgo f
recombinant mouse IL-17A for 24 hours prior to similar lung
processing.
Statistics
Data were analyzed by unpaired two-tailed t-test or by one-way
ANOVA where appropriate. For multiple comparisons, following
ANOVA, data were compared by Tukey test. Analyses with a
resultant p,0.05 were determined significant, additionally p,0.10
is also reported as a trend. Data are presented as mean 6 standard
error of the mean. All studies were repeated at a minimum of two
times with the resultant combined data presented, except for
MTEC gene expression data where representative data is shown.
All analyses were conducted with the Microsoft Excel software
package.
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